Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Free Report) have earned an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $64.29.

A number of analysts recently issued reports on JSPR shares. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 price objective on the stock. TD Cowen started coverage on Jasper Therapeutics in a report on Monday, March 18th. They set an “outperform” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Tuesday. Oppenheimer reissued an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a report on Thursday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Wednesday, May 15th.

Check Out Our Latest Stock Report on JSPR

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $22.12 on Friday. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The business’s fifty day moving average price is $23.32 and its 200-day moving average price is $18.75. The stock has a market capitalization of $333.13 million, a PE ratio of -3.93 and a beta of 2.24.

Jasper Therapeutics (NASDAQ:JSPRGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.23. As a group, equities analysts expect that Jasper Therapeutics will post -4.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors have recently modified their holdings of the company. Ieq Capital LLC bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $43,000. Monaco Asset Management SAM bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $197,000. Virtu Financial LLC bought a new position in shares of Jasper Therapeutics during the 1st quarter valued at about $306,000. Fernwood Investment Management LLC increased its position in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Jasper Therapeutics during the 1st quarter valued at about $599,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

(Get Free Report

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Read More

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.